Compare Amphastar Pharmaceuticals Inc (AMPH) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Williams-Sonoma, Inc. trades at $221.79 (market cap $26.11B). The key difference: Williams-Sonoma, Inc. is far larger — about 31.6× Amphastar Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.37% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WSM | |
|---|---|---|
Market Cap | $826.08M | $26.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $240.06 |
52-Week Low | $16.87 | $163.62 |
Enterprise Value | $1.22B | $26.95B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Williams-Sonoma (WSM) trades at $221.75, up 0.9% with a bullish technical signal. The company demonstrates strong profitability with 46.1% gross margins and 54% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.76 quarterly dividend. Analyst consensus is mixed with 29% buy ratings but a $215.50 price target below current levels.
WSM faces headwinds from revenue contraction and competitive pressures in home furnishings, though strong margins and consistent earnings beats provide support. The stock trades at premium valuations (P/E 24.9, P/S 3.4) requiring sustained execution. Near-term direction hinges on Q2 2026 earnings due next, with technical support at $217 and resistance at $223.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
